The startup develops novel pharmacological agents for use in vaccines targeting respiratory viruses, specifically focusing on influenza and other infectious diseases. By enhancing the efficacy of vaccines, the company enables healthcare professionals to improve patient recovery outcomes.
Funding
$12.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current vaccines for respiratory viruses, such as influenza and SARS-CoV-2, often exhibit limited effectiveness, particularly against new and emerging variants. Traditional vaccine production methods can also be slow and may not provide sufficient breadth of protection. Furthermore, maintaining cold chain storage for distribution poses logistical challenges, especially in low-resource settings.
Solution
Mynvax is developing novel, recombinant protein subunit vaccines that are designed for enhanced efficacy, broader protection, and improved thermostability. Utilizing structure-based protein stabilization and engineering, Mynvax identifies and incorporates stabilizing mutations into viral surface proteins, such as the hemagglutinin (HA) protein of influenza and the spike glycoprotein of SARS-CoV-2. This approach aims to elicit robust neutralizing antibody responses and confer protection against a wide range of viral strains and variants. The resulting vaccine candidates are designed to be thermostable, reducing the reliance on strict cold chain requirements and facilitating distribution to diverse geographical locations.
Target Audience
Mynvax's primary target audience includes public health organizations, vaccine manufacturers, and global health initiatives focused on preventing and controlling respiratory viral infections, particularly in regions with limited access to cold chain infrastructure.
Features
- Recombinant protein subunit vaccines designed for influenza and SARS-CoV-2
- Structure-based protein stabilization and engineering to enhance immunogenicity
- Thermostable formulations that can withstand storage at room temperature (up to 40°C) for extended periods
- Broad spectrum of neutralization against current and emerging viral variants
- Mynflu001: An adjuvanted quadrivalent recombinant subunit influenza vaccine entering clinical development
- Mynflu002: An adjuvanted recombinant multivalent influenza vaccine with novel, conserved antigens
- Myncov1003: A clinical-stage, adjuvanted protein subunit vaccine based on the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein
- Myncov1006: A pre-clinical stage candidate with an engineered Spike protein, including the RBD and conserved regions
- Manufacturing process utilizing mammalian, P. pastoris, and insect cells